Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Gains from Investment Securities: 2013-2025

Historic Gains from Investment Securities for Theravance Biopharma (TBPH) over the last 10 years, with Sep 2025 value amounting to $12.8 million.

  • Theravance Biopharma's Gains from Investment Securities rose 3116.37% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year increase of 720.12%. This contributed to the annual value of $2.7 million for FY2024, which is 6.36% up from last year.
  • As of Q3 2025, Theravance Biopharma's Gains from Investment Securities stood at $12.8 million, which was up 59.00% from $8.0 million recorded in Q2 2025.
  • Theravance Biopharma's Gains from Investment Securities' 5-year high stood at $115.5 million during Q4 2022, with a 5-year trough of $347,000 in Q2 2022.
  • Its 3-year average for Gains from Investment Securities is $2.5 million, with a median of $583,000 in 2023.
  • Per our database at Business Quant, Theravance Biopharma's Gains from Investment Securities soared by 25,286.59% in 2022 and then tumbled by 99.55% in 2023.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Gains from Investment Securities stood at $455,000 in 2021, then surged by 25,286.59% to $115.5 million in 2022, then plummeted by 99.55% to $518,000 in 2023, then climbed by 1.93% to $528,000 in 2024, then skyrocketed by 3,116.37% to $12.8 million in 2025.
  • Its Gains from Investment Securities stands at $12.8 million for Q3 2025, versus $8.0 million for Q2 2025 and $1.9 million for Q1 2025.